Atlas Trials

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

Clinical trial NCT04488016 · COMPLETED

Trial details

NCT number
NCT04488016
Sponsor
AstraZeneca
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
BioavailabilityB-cell Lymphoid Cancer
Start date
2020-06-24
Primary completion
2021-01-20
Enrollment
54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.